Does LOSARTAN Cause Second primary malignancy? 8 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Second primary malignancy have been filed in association with LOSARTAN (Losartan Potassium). This represents 0.0% of all adverse event reports for LOSARTAN.
8
Reports of Second primary malignancy with LOSARTAN
0.0%
of all LOSARTAN reports
2
Deaths
6
Hospitalizations
How Dangerous Is Second primary malignancy From LOSARTAN?
Of the 8 reports, 2 (25.0%) resulted in death, 6 (75.0%) required hospitalization, and 1 (12.5%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LOSARTAN. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does LOSARTAN Cause?
Drug ineffective (1,640)
Dizziness (1,553)
Headache (1,256)
Dyspnoea (1,185)
Malaise (1,149)
Hypotension (1,139)
Fatigue (1,116)
Acute kidney injury (1,100)
Cough (1,073)
Blood pressure increased (950)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which LOSARTAN Alternatives Have Lower Second primary malignancy Risk?
LOSARTAN vs LOSARTAN\LOSARTAN
LOSARTAN vs LOTEPREDNOL ETABONATE
LOSARTAN vs LOTEPREDNOL ETABONATE\TOBRAMYCIN
LOSARTAN vs LOTILANER
LOSARTAN vs LOVASTATIN